Fig 5.

Immunosera depleted with VV-susceptible PHL subsets reduced their blocking activity against VV binding. Immunosera raised against DRMs from monocytes were diluted 1:10 in PBS and then treated with activated T cells (40 × 10⁶), or immunosera raised against DRMs from activated T cells were treated with monocytes (40 × 10⁶) to deplete Abs. Ab-depleted immunosera were then used to block VV binding to monocytes (A), B cells (B), and activated T cells (C). MFI of YFP data represent the immunoserum-mediated blockage of VV binding to PHL subsets of 6 blood donors. Data were compared using Tukey's ANOVA assay. Anti-M DRMs, immunosera raised against DRMs of monocytes and incubated with activated T cells to deplete Abs; Anti-Act T DRMs, immunosera raised against DRMs of activated T cells and incubated with monocytes to deplete Abs; *, P < 0.05.